Goodwin is presenting a two-part publication series covering life sciences trends involving license deals, M&A, and financing for Greater China’s life sciences sector. ...more
11/11/2024
/ Acquisitions ,
AstraZeneca ,
Biotechnology ,
Bristol-Myers Squibb ,
China ,
Johnson & Johnson ,
Life Sciences ,
Medical Devices ,
Mergers ,
Novartis ,
Pharmaceutical Industry ,
Popular
On Jan 9, Coherus BioSciences, Inc. (“Coherus”) announced that it has agreed to acquire the exclusive commercialization rights to FYB203, a biosimilar referencing EYLEA (aflibercept) from Klinge Biopharma GmbH (“Klinge...more
According to PwC, “2022 has been a challenging year for M&A in the pharmaceutical and life sciences sector, with both deal value and volume at multiyear lows thanks to overall macro headwinds coupled with broad-based market...more